Dear All, The 27 Sep 2024 newsletter (“Without action, AMR costs go from $66b to $159b/yr by 2050”) reviewed a report by Anthony McDonnell and a team led by the Center for Global Development in which they created economic estimates of the costs/values of action (and inaction) through 2050, based on 5 possible action/ inaction scenarios.
Dear All, I have learned that UK’s MHRA (Medicines & Healthcare products Regulatory Agency) is recruiting for the role of Chief Medical and Scientific Officer. As you would expect, the role is very senior! The person in the role will: Represent the MHRA across the medical and scientific communities Act as a senior advocate for evidence-based, effective
Dear All, Back in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A description of the desired attributes of a drug) for products for enteric fever, gonorrhea, neonatal sepsis, and urinary tract infections as guides for developers (see the 1 Sep 2019 newsletter for the original call for input and the link
Dear All (and with thanks to Damiano for taking the lead on this newsletter), We wrote previously in (i) the 7 Dec 2023 newsletter (“How Italy should Push and Pull: New report as Italy takes the 2024 G7 chair”), (ii) the 17 Oct 2024 newsletter (“Italy funds CARB-X and announces pull incentive!”), and finally (iii) the 9 Jan
Dear All, BARDA have published an RFP (Request for Proposals) under which it would support clinical development and then stockpiling of an antibiotic for “treatment of bacterial pneumonia or bloodstream infections.” Here are the data you need to get started: RFP #: 75A50125R00005 https://sam.gov/opp/494fc05d7c4940abad0273cdb465079a/view Submission deadline is 26 Aug 2025 Quoting liberally from the online
Dear All (and with thanks to Vega Masignani for co-authoring this newsletter), Waaaay back in 2019 (pre-COVID … remember that?), Wellcome put out a call for grants focused on understanding the value of vaccines in combatting AMR (4 June 2019 newsletter entitled “Why vaccines for AMR? What is their value? Grant opportunity for research on
Dear All (addendum: see also the 22 Dec 2025 follow-up newsletter), I wrote in a 12 Dec 2024 newsletter (“Mirror Bacteria: An AMR threat of unprecedented magnitude”) about the really disturbing possible threat from creation of “mirror” bacteria in which all chiral elements of the bacterium are replaced by their enantiomeric counterparts. Such bacteria are predicted to
Dear All, An updated version of FDA’s very helpful Q&A entitled “Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases – Questions and Answers” has just been released. Here are the links you need to get started: The new June 2025 guidance itself The webpage about the guidance
Dear All, Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR; 1 Oct 2024 newsletter and our dedicated UNGA 2024 webpage), you will hopefully recall the commitment to create an Independent Panel on Evidence for Action against AMR (IPEA). The broad idea is the
Dear All (Deeply wonkish alert! Settle in! Great stuff here!): For today, we have a deep dive into the ongoing work in the EU to develop a set of realistic pull incentives using our best understanding to date of realistic choices. If the idea of Pull (and Push) is new to you, please check out